Table of Contents United States Hemoglobinopathies Drugs Market Report 2018 1 Hemoglobinopathies Drugs Overview 1.1 Product Overview and Scope of Hemoglobinopathies Drugs 1.2 Classification of Hemoglobinopathies Drugs by Product Category 1.2.1 United States Hemoglobinopathies Drugs Market Size (Sales Volume) Comparison by Type (2013-2025) 1.2.2 United States Hemoglobinopathies Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2017 1.2.3 Thalassemia Therapy 1.2.4 Sickle Cell Disease(SCD) Therapy 1.2.5 Other Therapy 1.3 United States Hemoglobinopathies Drugs Market by Application/End Users 1.3.1 United States Hemoglobinopathies Drugs Market Size (Consumption) and Market Share Comparison by Application (2013-2025) 1.3.2 Alpha Thalassemia 1.3.3 Beta thalassemia 1.3.4 Sickle Cell Disease 1.3.5 Hb Variants Diseases 1.4 United States Hemoglobinopathies Drugs Market by Region 1.4.1 United States Hemoglobinopathies Drugs Market Size (Value) Comparison by Region (2013-2025) 1.4.2 The West Hemoglobinopathies Drugs Status and Prospect (2013-2025) 1.4.3 Southwest Hemoglobinopathies Drugs Status and Prospect (2013-2025) 1.4.4 The Middle Atlantic Hemoglobinopathies Drugs Status and Prospect (2013-2025) 1.4.5 New England Hemoglobinopathies Drugs Status and Prospect (2013-2025) 1.4.6 The South Hemoglobinopathies Drugs Status and Prospect (2013-2025) 1.4.7 The Midwest Hemoglobinopathies Drugs Status and Prospect (2013-2025) 1.5 United States Market Size (Value and Volume) of Hemoglobinopathies Drugs (2013-2025) 1.5.1 United States Hemoglobinopathies Drugs Sales and Growth Rate (2013-2025) 1.5.2 United States Hemoglobinopathies Drugs Revenue and Growth Rate (2013-2025) 2 United States Hemoglobinopathies Drugs Market Competition by Players/Suppliers 2.1 United States Hemoglobinopathies Drugs Sales and Market Share of Key Players/Suppliers (2013-2018) 2.2 United States Hemoglobinopathies Drugs Revenue and Share by Players/Suppliers (2013-2018) 2.3 United States Hemoglobinopathies Drugs Average Price by Players/Suppliers (2013-2018) 2.4 United States Hemoglobinopathies Drugs Market Competitive Situation and Trends 2.4.1 United States Hemoglobinopathies Drugs Market Concentration Rate 2.4.2 United States Hemoglobinopathies Drugs Market Share of Top 3 and Top 5 Players/Suppliers 2.4.3 Mergers & Acquisitions, Expansion in United States Market 2.5 United States Players/Suppliers Hemoglobinopathies Drugs Manufacturing Base Distribution, Sales Area, Product Type 3 United States Hemoglobinopathies Drugs Sales (Volume) and Revenue (Value) by Region (2013-2018) 3.1 United States Hemoglobinopathies Drugs Sales and Market Share by Region (2013-2018) 3.2 United States Hemoglobinopathies Drugs Revenue and Market Share by Region (2013-2018) 3.3 United States Hemoglobinopathies Drugs Price by Region (2013-2018) 4 United States Hemoglobinopathies Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2013-2018) 4.1 United States Hemoglobinopathies Drugs Sales and Market Share by Type (Product Category) (2013-2018) 4.2 United States Hemoglobinopathies Drugs Revenue and Market Share by Type (2013-2018) 4.3 United States Hemoglobinopathies Drugs Price by Type (2013-2018) 4.4 United States Hemoglobinopathies Drugs Sales Growth Rate by Type (2013-2018) 5 United States Hemoglobinopathies Drugs Sales (Volume) by Application (2013-2018) 5.1 United States Hemoglobinopathies Drugs Sales and Market Share by Application (2013-2018) 5.2 United States Hemoglobinopathies Drugs Sales Growth Rate by Application (2013-2018) 5.3 Market Drivers and Opportunities 6 United States Hemoglobinopathies Drugs Players/Suppliers Profiles and Sales Data 6.1 Gamida Cell 6.1.1 Company Basic Information, Manufacturing Base and Competitors 6.1.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.1.2.1 Product A 6.1.2.2 Product B 6.1.3 Gamida Cell Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.1.4 Main Business/Business Overview 6.2 Alnylam Pharmaceuticals 6.2.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.2.2.1 Product A 6.2.2.2 Product B 6.2.3 Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.2.4 Main Business/Business Overview 6.3 Biogen Idec 6.3.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.3.2.1 Product A 6.3.2.2 Product B 6.3.3 Biogen Idec Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.3.4 Main Business/Business Overview 6.4 Sangamo BioSciences Inc. 6.4.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.4.2.1 Product A 6.4.2.2 Product B 6.4.3 Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.4.4 Main Business/Business Overview 6.5 Genetix Pharmaceuticals/Bluebird Bio 6.5.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.5.2.1 Product A 6.5.2.2 Product B 6.5.3 Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.5.4 Main Business/Business Overview 6.6 Global Blood Therapeutics Inc. 6.6.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.6.2.1 Product A 6.6.2.2 Product B 6.6.3 Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.6.4 Main Business/Business Overview 6.7 Pfizer Inc. 6.7.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.7.2.1 Product A 6.7.2.2 Product B 6.7.3 Pfizer Inc. Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.7.4 Main Business/Business Overview 6.8 Mast Therapeutics 6.8.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.8.2.1 Product A 6.8.2.2 Product B 6.8.3 Mast Therapeutics Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.8.4 Main Business/Business Overview 6.9 Emmaus Life Sciences, Inc. 6.9.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.9.2.1 Product A 6.9.2.2 Product B 6.9.3 Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.9.4 Main Business/Business Overview 6.10 Prolong Pharmaceuticals 6.10.2 Hemoglobinopathies Drugs Product Category, Application and Specification 6.10.2.1 Product A 6.10.2.2 Product B 6.10.3 Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales, Revenue, Price and Gross Margin (2013-2018) 6.10.4 Main Business/Business Overview 6.11 Celgene Corporation 6.12 HemaQuest Pharmaceuticals 7 Hemoglobinopathies Drugs Manufacturing Cost Analysis 7.1 Hemoglobinopathies Drugs Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Price Trend of Key Raw Materials 7.1.3 Key Suppliers of Raw Materials 7.1.4 Market Concentration Rate of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.2.1 Raw Materials 7.2.2 Labor Cost 7.2.3 Manufacturing Expenses 7.3 Manufacturing Process Analysis of Hemoglobinopathies Drugs 8 Industrial Chain, Sourcing Strategy and Downstream Buyers 8.1 Hemoglobinopathies Drugs Industrial Chain Analysis 8.2 Upstream Raw Materials Sourcing 8.3 Raw Materials Sources of Hemoglobinopathies Drugs Major Manufacturers in 2017 8.4 Downstream Buyers 9 Marketing Strategy Analysis, Distributors/Traders 9.1 Marketing Channel 9.1.1 Direct Marketing 9.1.2 Indirect Marketing 9.1.3 Marketing Channel Development Trend 9.2 Market Positioning 9.2.1 Pricing Strategy 9.2.2 Brand Strategy 9.2.3 Target Client 9.3 Distributors/Traders List 10 Market Effect Factors Analysis 10.1 Technology Progress/Risk 10.1.1 Substitutes Threat 10.1.2 Technology Progress in Related Industry 10.2 Consumer Needs/Customer Preference Change 10.3 Economic/Political Environmental Change 11 United States Hemoglobinopathies Drugs Market Size (Value and Volume) Forecast (2018-2025) 11.1 United States Hemoglobinopathies Drugs Sales Volume, Revenue Forecast (2018-2025) 11.2 United States Hemoglobinopathies Drugs Sales Volume Forecast by Type (2018-2025) 11.3 United States Hemoglobinopathies Drugs Sales Volume Forecast by Application (2018-2025) 11.4 United States Hemoglobinopathies Drugs Sales Volume Forecast by Region (2018-2025) 12 Research Findings and Conclusion 13 Appendix 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Disclaimer

List of Tables and Figures Figure Product Picture of Hemoglobinopathies Drugs Figure United States Hemoglobinopathies Drugs Market Size (K Units) by Type (2013-2025) Figure United States Hemoglobinopathies Drugs Sales Volume Market Share by Type (Product Category) in 2017 Figure Thalassemia Therapy Product Picture Figure Sickle Cell Disease(SCD) Therapy Product Picture Figure Other Therapy Product Picture Figure United States Hemoglobinopathies Drugs Market Size (K Units) by Application (2013-2025) Figure United States Sales Market Share of Hemoglobinopathies Drugs by Application in 2017 Figure Alpha Thalassemia Examples Table Key Downstream Customer in Alpha Thalassemia Figure Beta thalassemia Examples Table Key Downstream Customer in Beta thalassemia Figure Sickle Cell Disease Examples Table Key Downstream Customer in Sickle Cell Disease Figure Hb Variants Diseases Examples Table Key Downstream Customer in Hb Variants Diseases Figure United States Hemoglobinopathies Drugs Market Size (Million USD) by Region (2013-2025) Figure The West Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2013-2025) Figure Southwest Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2013-2025) Figure The Middle Atlantic Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2013-2025) Figure New England Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2013-2025) Figure The South of US Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2013-2025) Figure The Midwest Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2013-2025) Figure United States Hemoglobinopathies Drugs Sales (K Units) and Growth Rate (2013-2025) Figure United States Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate (2013-2025) Figure United States Hemoglobinopathies Drugs Market Major Players Product Sales Volume (K Units) (2013-2018) Table United States Hemoglobinopathies Drugs Sales (K Units) of Key Players/Suppliers (2013-2018) Table United States Hemoglobinopathies Drugs Sales Share by Players/Suppliers (2013-2018) Figure 2017 United States Hemoglobinopathies Drugs Sales Share by Players/Suppliers Figure 2017 United States Hemoglobinopathies Drugs Sales Share by Players/Suppliers Figure United States Hemoglobinopathies Drugs Market Major Players Product Revenue (Million USD) (2013-2018) Table United States Hemoglobinopathies Drugs Revenue (Million USD) by Players/Suppliers (2013-2018) Table United States Hemoglobinopathies Drugs Revenue Share by Players/Suppliers (2013-2018) Figure 2017 United States Hemoglobinopathies Drugs Revenue Share by Players/Suppliers Figure 2017 United States Hemoglobinopathies Drugs Revenue Share by Players/Suppliers Table United States Market Hemoglobinopathies Drugs Average Price (USD/Unit) of Key Players/Suppliers (2013-2018) Figure United States Market Hemoglobinopathies Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2017 Figure United States Hemoglobinopathies Drugs Market Share of Top 3 Players/Suppliers Figure United States Hemoglobinopathies Drugs Market Share of Top 5 Players/Suppliers Table United States Players/Suppliers Hemoglobinopathies Drugs Manufacturing Base Distribution and Sales Area Table United States Players/Suppliers Hemoglobinopathies Drugs Product Category Table United States Hemoglobinopathies Drugs Sales (K Units) by Region (2013-2018) Table United States Hemoglobinopathies Drugs Sales Share by Region (2013-2018) Figure United States Hemoglobinopathies Drugs Sales Share by Region (2013-2018) Figure United States Hemoglobinopathies Drugs Sales Market Share by Region in 2017 Table United States Hemoglobinopathies Drugs Revenue (Million USD) and Market Share by Region (2013-2018) Table United States Hemoglobinopathies Drugs Revenue Share by Region (2013-2018) Figure United States Hemoglobinopathies Drugs Revenue Market Share by Region (2013-2018) Figure United States Hemoglobinopathies Drugs Revenue Market Share by Region in 2017 Table United States Hemoglobinopathies Drugs Price (USD/Unit) by Region (2013-2018) Table United States Hemoglobinopathies Drugs Sales (K Units) by Type (2013-2018) Table United States Hemoglobinopathies Drugs Sales Share by Type (2013-2018) Figure United States Hemoglobinopathies Drugs Sales Share by Type (2013-2018) Figure United States Hemoglobinopathies Drugs Sales Market Share by Type in 2017 Table United States Hemoglobinopathies Drugs Revenue (Million USD) and Market Share by Type (2013-2018) Table United States Hemoglobinopathies Drugs Revenue Share by Type (2013-2018) Figure Revenue Market Share of Hemoglobinopathies Drugs by Type (2013-2018) Figure Revenue Market Share of Hemoglobinopathies Drugs by Type in 2017 Table United States Hemoglobinopathies Drugs Price (USD/Unit) by Types (2013-2018) Figure United States Hemoglobinopathies Drugs Sales Growth Rate by Type (2013-2018) Table United States Hemoglobinopathies Drugs Sales (K Units) by Application (2013-2018) Table United States Hemoglobinopathies Drugs Sales Market Share by Application (2013-2018) Figure United States Hemoglobinopathies Drugs Sales Market Share by Application (2013-2018) Figure United States Hemoglobinopathies Drugs Sales Market Share by Application in 2017 Table United States Hemoglobinopathies Drugs Sales Growth Rate by Application (2013-2018) Figure United States Hemoglobinopathies Drugs Sales Growth Rate by Application (2013-2018) Table Gamida Cell Basic Information List Table Gamida Cell Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Gamida Cell Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Gamida Cell Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Gamida Cell Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Alnylam Pharmaceuticals Basic Information List Table Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Alnylam Pharmaceuticals Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Alnylam Pharmaceuticals Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Biogen Idec Basic Information List Table Biogen Idec Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Biogen Idec Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Biogen Idec Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Biogen Idec Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Sangamo BioSciences Inc. Basic Information List Table Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Sangamo BioSciences Inc. Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Sangamo BioSciences Inc. Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Genetix Pharmaceuticals/Bluebird Bio Basic Information List Table Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Genetix Pharmaceuticals/Bluebird Bio Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Global Blood Therapeutics Inc. Basic Information List Table Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Global Blood Therapeutics Inc. Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Pfizer Inc. Basic Information List Table Pfizer Inc. Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Pfizer Inc. Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Pfizer Inc. Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Pfizer Inc. Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Mast Therapeutics Basic Information List Table Mast Therapeutics Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Mast Therapeutics Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Mast Therapeutics Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Mast Therapeutics Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Emmaus Life Sciences, Inc. Basic Information List Table Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Emmaus Life Sciences, Inc. Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Prolong Pharmaceuticals Basic Information List Table Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018) Figure Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales Growth Rate (2013-2018) Figure Prolong Pharmaceuticals Hemoglobinopathies Drugs Sales Market Share in United States (2013-2018) Figure Prolong Pharmaceuticals Hemoglobinopathies Drugs Revenue Market Share in United States (2013-2018) Table Celgene Corporation Basic Information List Table HemaQuest Pharmaceuticals Basic Information List Table Production Base and Market Concentration Rate of Raw Material Figure Price Trend of Key Raw Materials Table Key Suppliers of Raw Materials Figure Manufacturing Cost Structure of Hemoglobinopathies Drugs Figure Manufacturing Process Analysis of Hemoglobinopathies Drugs Figure Hemoglobinopathies Drugs Industrial Chain Analysis Table Raw Materials Sources of Hemoglobinopathies Drugs Major Players/Suppliers in 2017 Table Major Buyers of Hemoglobinopathies Drugs Table Distributors/Traders List Figure United States Hemoglobinopathies Drugs Sales Volume (K Units) and Growth Rate Forecast (2018-2025) Figure United States Hemoglobinopathies Drugs Revenue (Million USD) and Growth Rate Forecast (2018-2025) Figure United States Hemoglobinopathies Drugs Price (USD/Unit) Trend Forecast (2018-2025) Table United States Hemoglobinopathies Drugs Sales Volume (K Units) Forecast by Type (2018-2025) Figure United States Hemoglobinopathies Drugs Sales Volume (K Units) Forecast by Type (2018-2025) Figure United States Hemoglobinopathies Drugs Sales Volume (K Units) Forecast by Type in 2025 Table United States Hemoglobinopathies Drugs Sales Volume (K Units) Forecast by Application (2018-2025) Figure United States Hemoglobinopathies Drugs Sales Volume (K Units) Forecast by Application (2018-2025) Figure United States Hemoglobinopathies Drugs Sales Volume (K Units) Forecast by Application in 2025 Table United States Hemoglobinopathies Drugs Sales Volume (K Units) Forecast by Region (2018-2025) Table United States Hemoglobinopathies Drugs Sales Volume Share Forecast by Region (2018-2025) Figure United States Hemoglobinopathies Drugs Sales Volume Share Forecast by Region (2018-2025) Figure United States Hemoglobinopathies Drugs Sales Volume Share Forecast by Region in 2025 Table Research Programs/Design for This Report Figure Bottom-up and Top-down Approaches for This Report Figure Data Triangulation Table Key Data Information from Secondary Sources Table Key Data Information from Primary Sources